Items tagged with Treatment
Common heartburn drugs could speed up tuberculosis treatment (post)
Researchers have discovered that over-the-counter drugs commonly used to treat heartburn could shorten the treatment of tuberculosis (TB). These drugs could also reduce the chances of the bacteria that causes TB from becoming drug resistant.
Invitation for public comments on draft WHO tuberculosis target product profiles (post)
The World Health Organization (WHO) invites all stakeholders to comment by 9 March 2023 on the latest drafts of the target regimen profiles (TRPs) for TB treatment and the target product profiles (TPPs) for tests for TB treatment monitoring and optimization, by means of online feedback forms.
Latest Union guide for diagnosis and management of TB in children and adolescents launches (post)
9 February 2023: Today, the fourth edition of The Union’s desk guide for diagnosis and management of tuberculosis (TB) in children and adolescents has been published.
Rifampicin dose escalation, higher starting dose helps patients with TB in ICU (post)
Dose escalation, guided by therapeutic drug monitoring, is an effective method to achieve target levels of rifampicin in those critically ill with TB.
Drug-susceptible TB: TB treatment strategy has potential to drastically slash therapy duration (TRUNCATE-TB trial) (post)
SEATTLE, February 22, 2023 -- An 8-week tuberculosis (TB) treatment strategy where additional therapy is reserved only for persistent disease or at relapse led to less overall treatment and similar clinical outcomes compared with the standard 6-month approach, an open-label randomized study showed.
Clinical trial for drug-sensitive and drug-resistant TB regimen evaluated shorter regimens (SimpliciTB trial) (post)
SEATTLE (February 20, 2023)—Results of TB Alliance’s SimpliciTB clinical trial were presented today at the 30th annual CROI 2023 conference. SimpliciTB was conducted to evaluate the BPaMZ regimen, consisting of bedaquiline (B), pretomanid (Pa), moxifloxacin (M), and pyrazinamide (Z). This combination previously showed high efficacy and treatment shortening potential in both preclinical evaluations and an early-stage clinical study in drug-resistant patients.
Sutezolid with 3-drug combo appears safe and effective in multidrug-resistant TB (post)
SEATTLE, February 22, 2023 -- Adding the oxazolidinone antibiotic sutezolid to a three-drug combination appeared to be safe and effective for people with multidrug-resistant tuberculosis (TB), according to a dose-finding phase II study.
Webinar: TB treatment trial results in context for communities (post)
Tuesday, March 14, 2023
8:00 am – 9:30 am ET
CROI 2023 TB research round up (post)
Treatment Action Group (TAG) released an overview of TB research data reported at the 30th Conference on Retroviruses and Opportunistic Infections (CROI 2023) held on 19-22 February 2023 in Seattle, Washington, USA. Highlights include the much-anticipated results of the SimpliciTB trial; additional analyses of the two-month TB treatment regimen studied in the TRUNCATE-TB trial; and the first clinical trial data on sutezolid since 2012.
What next after shortened TB treatment fails in key trial? (post)
Spotlight reflected on the results from two TB trials - SimpliciTB and TRUNCATE-TB, reported at the 30th Conference on Retroviruses and Opportunistic Infections (CROI 2023) held on 19-22 February 2023 in Seattle, Washington, USA, featuring TAG TB Co-Director Lindsay McKenna, elaborating on what comes next as an alternative to the six-month drug-susceptible standard of TB care.
Page 68 of 106 · Total posts: 0
←First 67 68 69 Last→